A prospective surveillance of cardiovascular events in antiplatelet-treated arteriosclerosis obliterans patients in Japan.
Latest Information Update: 20 Jan 2026
At a glance
- Drugs Sarpogrelate (Primary) ; Antiplatelets
- Indications Arteriosclerosis obliterans; Cardiovascular disorders; Embolism and thrombosis
- Focus Therapeutic Use
- Acronyms SEASON
- Sponsors Tanabe Pharma Corporation
Most Recent Events
- 12 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 11 May 2011 New trial record